1-hexadecanoyl-2-[(15Z)-tetracosenoyl]-sn-glycero-3-phosphocholine

Metabolite details

Identifier

XUCOLWONUSFHRC-QFQSVWFISA-N

InChI Key

XUCOLWONUSFHRC-QFQSVWFISA-N

IUPAC name

(2R)-3-(hexadecanoyloxy)-2-{[(15Z)-tetracos-15-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate

Preferred name

1-hexadecanoyl-2-[(15Z)-tetracosenoyl]-sn-glycero-3-phosphocholine

INN name

—

Synonym

1-Palmitoyl-2-nervonoyl-sn-glycero-3-phosphocholine

ChEBI

CHEBI:86197

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Effect of L-carnitine administration on lipid and metabolite content in sheep infraspinatus muscle after tendon release
• Distinct succinate modifying products are clinically diagnostic and prognostic biomarkers for fumarate hydratase deficient renal cell carcinoma
• Lipidomic Changes in the Liver of Beagle Dogs Associated with Toxocara canis Infection
• Global Analyses of Selective Insulin Resistance in Hepatocytes due to Palmitate Lipotoxicity
• Flow cytometry has a significant impact on the cellular metabolome (Lipidomic LC-MS assay)
• PatA mediates biofilm formation and drugs resistance through regulating the synthesis of glycolipids and lipids in mycobacterium PatA mediates a novel mycolic acid synthesis pathway and regulates biofilm formation in mycobacterium
• LION-web validation lipidomics experiments (FA-incorporation, membrane fluidty)

Observed in differential profiles

• Control_16.6_months_vs_Treatment_16.6_months
• Normal_control_no_tumor_vs_FH_deficient_RCC
• Control_12h_vs_Toxocara canis_12h
• Control_vs_Palmitate
• G1_Ctrl_vs_G2_Ab
• wild_type_vs_patA_deletion
• BSA_Control_vs_AA